| Trial ID: | L4641 |
| Source ID: | NCT00515723
|
| Associated Drug: |
Risperidone
|
| Title: |
Glucose and Lipid Metabolism on Antipsychotic Medication
|
| Acronym: |
Glulipid
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00515723/results
|
| Conditions: |
Schizophrenia|Schizoaffective Disorder|Type 2 Diabetes Mellitus|Hyperglycemia
|
| Interventions: |
DRUG: risperidone|DRUG: olanzapine|DRUG: quetiapine|DRUG: ziprasidone
|
| Outcome Measures: |
Primary: DEXA Total Fat, This study hypothesized that antipsychotic treatment would increase total body fat, as measured by whole body dual energy x-ray absorptiometry (DEXA), with larger adverse effects for olanzapine., The relevant time points include baseline, week 6 and week 12.|Clamp Derived Insulin Sensitivity (mg/kg/Min), This study hypothesized that antipsychotic treatment would decrease insulin sensitivity, with larger adverse effects for olanzapine. Insulin sensitivity describes how sensitive the body is to the effects of insulin., The relevant time points include baseline and week 12. |
|
| Sponsor/Collaborators: |
Sponsor: Washington University School of Medicine | Collaborators: National Institute of Mental Health (NIMH)
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
|
| Enrollment: |
96
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2001-09
|
| Completion Date: |
2008-12
|
| Results First Posted: |
2019-10-02
|
| Last Update Posted: |
2019-10-02
|
| Locations: |
Washington Univeristy School of Medicine, Saint Louis, Missouri, 63110, United States|Washington University School of Medicine, Psychiatry Dept., Saint Louis, Missouri, 63110, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00515723
|
